“At Genetic Technologies, we are passionate about developing and bringing to market next generation products in the women’s health space. We are extremely excited about our flagship product, BREVAGenplus, as it offers a simple solution for taking proactive measures to better understand the personal risk of developing breast cancer, a disease that will affect 1 in 8 women in their lifetime.
Each year over 240,000 new cases of this debilitating and often deadly form of cancer are diagnosed in the U.S. What is equally daunting is that up to 85% of breast cancer cases are diagnosed as sporadic breast cancer, and occur in women with little to no family history of the disease. These women deserve the ability to better understand their risk of developing breast cancer, and this is where BREVAGenplus can help.
BREVAGenplus is a test that will assess the risk for developing sporadic breast cancer. The test is performed off of a cheek swab that is collected at the health care provider’s office. Our mission is to identify women at increased risk to potentially PREVENT breast cancer from developing. Shouldn’t you know your risk?”